Amyloid Precursor Protein (APP) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Amyloid Precursor Protein (APP) – Pipeline Review, H2 2016’, provides in depth analysis on Amyloid Precursor Protein (APP) targeted pipeline therapeutics.

The report provides comprehensive information on the Amyloid Precursor Protein (APP), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Amyloid Precursor Protein (APP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Amyloid Precursor Protein (APP)

The report reviews Amyloid Precursor Protein (APP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Amyloid Precursor Protein (APP) targeted therapeutics and enlists all their major and minor projects

The report assesses Amyloid Precursor Protein (APP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Amyloid Precursor Protein (APP) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Amyloid Precursor Protein (APP)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Amyloid Precursor Protein (APP) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

CereSpir Incorporated

QR Pharma, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Amyloid Precursor Protein (APP) Overview 6

Therapeutics Development 7

Amyloid Precursor Protein (APP) - Products under Development by Stage of Development 7

Amyloid Precursor Protein (APP) - Products under Development by Therapy Area 8

Amyloid Precursor Protein (APP) - Products under Development by Indication 9

Amyloid Precursor Protein (APP) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Amyloid Precursor Protein (APP) - Products under Development by Companies 12

Amyloid Precursor Protein (APP) - Products under Development by Universities/Institutes 14

Amyloid Precursor Protein (APP) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 19

Amyloid Precursor Protein (APP) - Companies Involved in Therapeutics Development 21

CereSpir Incorporated 21

QR Pharma, Inc. 22

Amyloid Precursor Protein (APP) - Drug Profiles 23

Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

ARN-2955 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

ARN-2966 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Bisnorcymserine - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

CSP-1103 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Posiphen - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Small Molecules to Inhibit Amyloid Beta Protein for Alzheimer's Disease - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

tropisetron hydrochloride - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Amyloid Precursor Protein (APP) - Dormant Projects 35

Amyloid Precursor Protein (APP) - Featured News & Press Releases 36

Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease 36

Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease 36

Nov 10, 2014: Buck Institute's First Clinical Trial Underway in Australia 37

Jun 09, 2014: Aria Announces Promising Results with Alzheimers Compound 37

Oct 10, 2013: QR Pharma and UCLA Awarded $3 Million USARMY Grant to Test Posiphen in Rat Models of Concussion and Blunt Head Trauma 38

Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON 38

Oct 22, 2012: QR Pharma's Posiphen Restores Brain Function, Cognition And Memory In Transgenic Alzheimer Mice 39

Jul 24, 2012: QR Pharma Starts Phase I Clinical Study For Bisnorcymserine 40

Jul 17, 2012: QR Pharma Announces Publication On Posiphen Clinical Trials Showing Promise For Alzheimer's Patients 40

Jul 10, 2012: QR Pharma To Present Clinical Data On Posiphen At Alzheimer's Association International Conference 41

Mar 06, 2012: QR Pharma Receives $468,000 From Michael J. Fox Foundation To Test Posiphen For Treatment Of Parkinson's Disease 41

Oct 13, 2011: QR Pharma Reports Results From SBIR Grant By NIA/NIH To Study Posiphen And Metabolites In Various Models 42

Jul 12, 2011: QR Pharma To Present Poster At International Conference On Alzheimer's Disease 42

Jun 02, 2011: QR Pharma To Present At Annual World Pharma Congress On Parkinson's Disease 43

Jan 19, 2011: QR Pharma To Present Poster At 44th Winter Conference On Brain Research 43

Appendix 45

Methodology 45

Coverage 45

Secondary Research 45

Primary Research 45

Expert Panel Validation 45

Contact Us 45

Disclaimer 46

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by CereSpir Incorporated, H2 2016 21

Pipeline by QR Pharma, Inc., H2 2016 22

Dormant Projects, H2 2016 35

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports